Genmab — August 2015
-
Ja, det er noget andet: For purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure, that is thought to predict clinical benefit, but is not itself a measure of clinical benefit.
-
Tak gutter.:-)
-
US ser noget dyster ud her til aften:-(
-
Her er også en lille teaser, imens vi venter http://www.biopharmadive.com/news/jjgenmab-unveil-promising-data-for-a-potential-multiple-myeloma-superstar/404734/
-
Tak Darvin for et godt indspark: http://www.proinvestor.com/?p=debat_1&postid=73067&thread=50&start=
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind